Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708570 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL1096270 | 0.78 | CES1 (0.55) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL3368202 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL11552318 | 0.75 | KEAP1 (0.54) | ALDH1A1KMT2AGAASMN1; SMN2LMNA | |
| SCHEMBL2186535 | 0.74 | CES1 (0.64) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL35280 | 0.74 | CES1 (0.50) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL2348652 | 0.74 | CES1 (0.50) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL6187432 | 0.74 | CES1 (0.50) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL2424223 | 0.74 | CES1 (0.50) | CES1CES2AKR1B1ALDH1A1KMT2A | |
| SCHEMBL1397309 | 0.74 | GAA (0.53) | CES1CES2AKR1B1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439179-B1 | NEW ORIPAVINE DERIVATIVES AND THEIR USES AS MEDICINES | INST PHARM & TOXICOLOGY AMMS (CN) | 2008-03-26 | — | — | EP | disclosed |
| US-7119100-B2 | Oripavine derivatives and their uses as pharmaceuticals | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES, P.L.A. CHINA (CN) | 2006-10-10 | — | — | US | disclosed |
| US-20050070564-A1 | Oripavine derivatives and their uses as medicines | ZHEJIANG XIANJU PHARMACEUTICALS CO., LTD. (CN) | 2005-03-31 | — | — | US | disclosed |
| EP-1439179-A1 | NEW ORIPAVINE DERIVATIVES AND THEIR USES AS MEDICINES | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2004-07-21 | — | — | EP | disclosed |
| US-4337341-A | 4a-Aryl-octahydro-1H-2-pyrindines | ELI LILLY AND COMPANY (US) | 1982-06-29 | — | — | US | disclosed |
| EP-0002937-A1 | Novel pyrindines and their preparation, formulations and use | ELI LILLY AND COMPANY (US) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070564-A1 | Oripavine derivatives and their uses as medicines | OPRK1, OPRM1, OPRD1 | CES1 216/4885CES2 85/4885AKR1B1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.